Orthogonal Biologics

United States Founded: 2020 • Age: 6 yrs Acquired By Cyrus Biotechnology
Protein drug manufacturing and research services are provided.

About Orthogonal Biologics

Orthogonal Biologics is a Healthcare company based in United States founded in 2020, and was acquired by Cyrus Biotechnology in December 2021. Protein drug manufacturing and research services are provided. Its chief executive, as recorded, is Erik Procko. Its focus areas include Biopharma Outsourcing, Diversified and Biologics. Its competitors include Catalent, Surrozen and Curia; 1 of its 3 listed competitors has raised funding.

Company details

Orthogonal Biologics was founded in 2020 and is based in the United States. Operations focus on the biotechnology sector, where manufacturing and research services for protein drugs are offered. These services support drug development processes, including production and scientific investigation. The company is led by CEO Erik Procko, with activities centered on advancing biologic therapies through specialized expertise.

Key Metrics

Investors in Orthogonal Biologics

Orthogonal Biologics has secured backing from 1 investor. Prominent investors backing the company include Cyrus Biotechnology.

All
InvestorDescriptionFounded YearDomainLocation
Cloud-based protein-modeling software is developed for drug discovery.
2014cyrusbio.comSeattle, United States
Premium access

Investor details for Orthogonal Biologics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Orthogonal Biologics

1 people are tracked at Orthogonal Biologics (1 in leadership).

NameRoleGroup
Erik Procko
CEOLeadership
Premium access

Complete people profiles for Orthogonal Biologics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Orthogonal Biologics

2 dated milestones of Orthogonal Biologics across 1 years, from founding to its latest funding, stage changes and deals.

  1. Founded Orthogonal Biologics is founded.
  2. Exit Acquired by Cyrus Biotechnology.

Competitors of Orthogonal Biologics

Orthogonal Biologics has 3 listed competitors in our database, 1 of them funded. They include Catalent, Surrozen and Curia.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
catalent.com2007Somerset, United States9,390
CDMO offering drug and biologics development services
surrozen.com2016San Francisco, United States$133M80
Selective Wnt agonists are developed for human tissue regeneration.
curiaglobal.com1991Albany, United States1,918
Drug research, development, testing, and consulting services are provided.
Premium access

Detailed competitors of Orthogonal Biologics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Orthogonal Biologics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M5,666
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Orthogonal Biologics

Orthogonal Biologics was founded in 2020.

Orthogonal Biologics is headquartered in United States.

Erik Procko is the CEO of Orthogonal Biologics, as recorded in our data.

Orthogonal Biologics was founded in 2020 and is based in the United States. Operations focus on the biotechnology sector, where manufacturing and research services for protein drugs are offered. These services support drug development processes, including production and scientific investigation. The company is led by CEO Erik Procko, with activities centered on advancing biologic therapies through specialized expertise.

Orthogonal Biologics's top competitors include Surrozen, Catalent and Curia.

Orthogonal Biologics has 1 investor. Key investors include Cyrus Biotechnology.

Yes. Orthogonal Biologics was acquired by Cyrus Biotechnology in December 2021.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available